SLC1A5 and breast carcinoma: In this study, we used isotopically labelled glutamine to resolve glutamine utilisation in two different breast cancer subtypes (TNBC vs. Luminal A), with the TNBC subtypes sensitive to inhibition of SLC1A5/ASCT2-mediated glutamine uptake.